From the earliest commercial kits used to test for pregnancy, to recent regulatory clearance allowing for home collection of samples for the early detection of colorectal cancer, lateral flow technology has remained the standard bearer in immunological, point-of-care testing. Predicated on the ability of antibodies to specifically bind both large proteins and analytes as small as traditional drugs and their metabolites, the range of possible targets for development of a lateral flow assay is nearly limitless.

While ubiquitous and convenient, traditional lateral flow technology is hampered by issues with sensitivity and accuracy. When considering a complex matrix such as saliva, these shortfalls are compounded and analysis times can increase to 20 minutes or more. By employing patented technologies, ALFA seeks to solve these problems without altering the sensitive chemistries involved in analyte detection.